RxDoctor Payments Data

Henry Redel, MD

Infectious Disease · East Brunswick, NJNPI 1750608642

Payments from drug & device makers

$1,475in general payments, 2019–2025

Across 39 payments — averaging $37.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$424
  • Organogenesis Inc.$285
  • Melinta Therapeutics, LLC$179
  • Shionogi Inc$163
  • Paratek Pharmaceuticals, Inc.$117
  • Merck$108
  • plus $198 from 5 others

What the payments were for

  • Food & beverage$1,475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,475 in reported general payments places this provider in the 60th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$306,210
Medicare patients
868
Services billed
41,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala80$322,036
JulucaDolutegravir/Rilpivirine20$72,181
TivicayDolutegravir Sodium26$60,806
PrezcobixDarunavir/Cobicistat22$55,545
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$50,609
DescovyEmtricitabine/Tenofov Alafenam21$45,936
Etravirine21$21,635
FarxigaDapagliflozin Propanediol12$6,776
Vancomycin Hcl20$2,502
Ceftazidime13$2,113
Testosterone11$1,852
Methenamine Hippurate27$1,651
Atorvastatin Calcium183$1,519
Amlodipine Besylate110$837
Cefadroxil21$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$424$367,972101 claims
Viiv Healthcare CompanyJuluca, Tivicay$41$132,98746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →